Spots Global Cancer Trial Database for unresectable metastatic colorectal cancer
Every month we try and update this database with for unresectable metastatic colorectal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | NCT06107413 | Unresectable Me... | ABBV-400 Bevacizumab Folinic Acid Fluorouracil Irinotecan | 18 Years - | AbbVie | |
| A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | NCT05068206 | Unresectable Me... | AK105 injection Anlotinib hydro... CapeOX Bevacizumab | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | NCT04991948 | Unresectable Me... | CYAD-101 FOLFOX Pembrolizumab | 18 Years - | Celyad Oncology SA | |
| OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer | NCT01802684 | Unresectable Me... | aflibercept | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | NCT06107413 | Unresectable Me... | ABBV-400 Bevacizumab Folinic Acid Fluorouracil Irinotecan | 18 Years - | AbbVie | |
| A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy | NCT04866108 | Unresectable Me... | fruquintinib pl... | 18 Years - | Beijing Friendship Hospital | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer | NCT04131803 | Unresectable Me... | Bifico combined... chemotherapy pl... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
